CRISPR Therapeutics AG (CRSP) Stock Price

CRSPStock

$60.90+5.07%52W

Market Cap$5.89B

P/E—

PEG Ratio—

Div yield—

Beta1.78

CRSP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-4.60%

Price vs S&P 500 (4W)16.98%

VGM Score51.22

Book Value / Share (Quarterly)$18.07

P/TBV (Annual)1.74x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)43.01%

Cash Flow / Share (Quarterly)$-3.87

Price vs S&P 500 (YTD)-3.12%

Net Profit Margin (TTM)-3368.72%

EPS (TTM)$-4.76

10-Day Avg Trading Volume1.61M

EPS Excl Extra (TTM)$-4.76

Revenue Growth (5Y)38.05%

EPS (Annual)$-6.47

ROI (Annual)-30.26%

Net Profit Margin (5Y Avg)-14346.95%

Cash / Share (Quarterly)$24.46

Revenue Growth QoQ (YoY)1041.37%

ROA (Last FY)-25.67%

Revenue Growth TTM (YoY)-64.80%

EBITD / Share (TTM)$-5.44

ROE (5Y Avg)-15.26%

Operating Margin (TTM)-3989.99%

Cash Flow / Share (Annual)$-3.87

P/B Ratio2.98x

P/B Ratio (Quarterly)3.01x

Net Income / Employee (Annual)$-1,479,900

EV / Revenue (TTM)411.11x

Net Interest Coverage (TTM)13.24x

ROA (TTM)-18.25%

EV / EBITDA (TTM)16.51x

EPS Incl Extra (Annual)$-6.47

Current Ratio (Annual)13.32x

Quick Ratio (Quarterly)17.79x

3-Month Avg Trading Volume1.71M

52-Week Price Return5.07%

Revenue / Employee (TTM)$34,100

Tangible BV / Share (Quarterly)$22.53

P/S Ratio (Annual)1484.55x

Asset Turnover (Annual)0.00x

52-Week High$78.48

Operating Margin (5Y Avg)-15260.63%

EPS Excl Extra (Annual)$-6.47

CapEx CAGR (5Y)7.09%

Tangible BV CAGR (5Y)15.52%

26-Week Price Return6.64%

Quick Ratio (Annual)13.28x

13-Week Price Return14.38%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)17.85x

Enterprise Value$5.51B

Revenue / Share Growth (5Y)29.76%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-2.31%

Revenue / Employee (Annual)$8,900

Pretax Margin (Annual)-16466.24%

Cash / Share (Annual)$20.60

3-Month Return Std Dev57.45%

Net Income / Employee (TTM)$-1,147,900

ROE (Last FY)-30.26%

Net Interest Coverage (Annual)-0.66x

EPS Basic Excl Extra (Annual)$-6.47

P/FCF (TTM)47.79x

Receivables Turnover (TTM)0.28x

Total Debt / Equity (Quarterly)0.34x

EPS Incl Extra (TTM)$-4.76

Receivables Turnover (Annual)0.28x

ROI (TTM)-21.06%

P/S Ratio (TTM)389.10x

Pretax Margin (5Y Avg)-14329.12%

Revenue / Share (Annual)$0.04

Tangible BV / Share (Annual)$22.53

Price vs S&P 500 (52W)-13.24%

Year-to-Date Return8.84%

5-Day Price Return7.75%

EPS Normalized (Annual)$-6.47

ROA (5Y Avg)-12.83%

Net Profit Margin (Annual)-16569.77%

Month-to-Date Return18.93%

Cash Flow / Share (TTM)$-4.22

EBITD / Share (Annual)$-7.17

Operating Margin (Annual)-18933.65%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-15.26%

LT Debt / Equity (Quarterly)0.34x

EPS Basic Excl Extra (TTM)$-4.76

P/TBV (Quarterly)1.74x

P/B Ratio (Annual)2.60x

Pretax Margin (TTM)-3346.08%

Book Value / Share (Annual)$20.04

Price vs S&P 500 (13W)11.59%

Beta1.78x

P/FCF (Annual)11.39x

Revenue / Share (TTM)$0.14

ROE (TTM)-24.39%

52-Week Low$44.12

vGradeD

gGradeB

mGradeB

vgmGradeC

CRSP Earnings Surprise History

Q2 25-1.29est. -1.40

Q3 25-1.17est. -1.29

Q4 25-1.37est. -1.23

Q1 26-1.28est. -1.23

Q2 26-0.94est. -1.18

CRSP Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.86

3.78

3.81

3.79

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About CRISPR Therapeutics AG

CRISPR Therapeutics is a gene editing company developing therapies based on CRISPR/Cas9 technology to treat genetically defined diseases. The company's first approved drug, Casgevy (co-developed with Vertex Pharmaceuticals), addresses sickle-cell disease and transfusion-dependent beta-thalassemia. CRISPR's pipeline includes gene editing programs in immuno-oncology, cardiovascular disease, and Type 1 diabetes.